XenoGesis and Sygnature Discovery

XenoGesis was acquired by Sygnature Discovery in September 2020.

Co-located at BioCity Nottingham, and with laboratories and facilities at Alderley Park, Sygnature Discovery is a leading integrated drug discovery CRO offering a unique, high-quality and tailored service.

Sygnature Discovery was founded by Dr Simon Hirst in 2004, and now employs over 400 scientists, serving clients across the globe with expertise in a variety of therapeutic areas.

Sygnature’s integrated drug discovery services include:

  • Chemistry
  • Computational science and informatics
  • In vitro pharmacology
  • In vivo pharmacology
  • Discovery toxicology
  • DMPK

Following the acquisition of XenoGesis, the DMPK team has doubled in size, capacity and capabilities. The two companies are currently working together through a transitional period to integrate the two teams under one brand.

To read the news story in full, click here, and for more information on Sygnature Discovery, visit their website.

For any queries regarding current or ongoing projects, please contact crm@xenogesis.com